(3R,4R,)-4-benzyl-1-t-butoxycarbonyl-3-hydroxymethylpyrrolidine | 637014-30-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (3R,4R,)-4-benzyl-1-t-butoxycarbonyl-3-hydroxymethylpyrrolidine
• 英文别名: (3R,4R)-3-benzyl-4-hydroxymethylpyrrolidine-1-carboxylic acid tert-butyl ester；tert-butyl (3R,4R)-3-benzyl-4-(hydroxymethyl)pyrrolidine-1-carboxylate；(3R*,4R*)-3-Benzyl-4-hydroxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester
• CAS: 637014-30-3
• 化学式: C₁₇H₂₅NO₃
• 分子量: 291.39
• InChiKey: MPUFILJCWZOHDB-LSDHHAIUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (3R,4R,)-4-benzyl-1-t-butoxycarbonyl-3-hydroxymethylpyrrolidine 在 jones' reagent 作用下， 以 丙酮 为溶剂， 反应 0.08h， 生成 (±)-trans-1-(tert-Butoxycarbonyl)-4-benzyl-pyrrolidine-3-carboxylic acid
  参考文献：
  名称：

  A Stereoselective Approach to Both 3,4-trans-Disubstituted Pyrrolidin-2-ones and Pyrrolidines. A Convenient Synthesis of (3R,4R)-4-Benzyl-3-pyrrolidinecarboxylic Acid

  摘要：

  DOI：

  10.3987/com-03-9854
• 作为产物：
  描述：

  ethyl 3-benzylacrylate 在 lithium aluminium tetrahydride 、 palladium hydroxide, 20 wt% on carbon 、 氨 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 乙醇 、 甲苯 为溶剂， 20.0 ℃ 、300.01 kPa 条件下， 反应 20.67h， 生成 (3R,4R,)-4-benzyl-1-t-butoxycarbonyl-3-hydroxymethylpyrrolidine
  参考文献：
  名称：

  Diastereodivergent Access to Syn and Anti 3,4-Substituted β-Fluoropyrrolidines: Enhancing or Reversing Substrate Preference

  摘要：

  A practical diastereodivergent access to beta-fluoropyrrolidines with two adjacent stereocenters has been demonstrated, by either enhancing or completely reversing the substrate control, in the diastereoselective fluorination of a series of diverse pyrrolidinyl carbaldehydes using organocatalysis. Furthermore, enamine catalysis has been successfully utilized for kinetic resolution, obtaining a fluorinated beta-prolinol analogue with two adjacent tetrasubstituted chiral centers in 95% ee from a racemic substrate.

  DOI：

  10.1021/acs.orglett.6b00293

文献信息

• PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS
  申请人：Rogel Olivier

  公开号：US20090247577A1

  公开（公告）日：2009-10-01

  Novel 3-mono-, 3,4-di- and 3,4,4,-tri-substituted pyrrolidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (disorder) that depends on the activity of beta-secretase and/or the generation of beta-amyloid and the subsequent aggregation into oligomers and fibrils; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on the activity of beta-secretase and/or the generation of beta-amyloid and the subsequent aggregation into oligomers and fibrils; pharmaceutical formulations comprising a said substituted pyrrolidine compound, and/or a method of treatment comprising administering a said substituted pyrrolidine compound. The substituted pyrrolidine compounds are especially of the formula I, wherein the substituents are as defined in the specification.

  小说3-单取代、3,4-双取代和3,4,4-三取代吡咯烷化合物，这些化合物用于诊断和治疗温血动物，特别是用于治疗依赖于β-分泌酶活性和/或β-淀粉样蛋白生成及其后续寡聚体和纤维聚集的疾病（紊乱）；该类化合物的使用用于制备用于治疗依赖于β-分泌酶活性和/或β-淀粉样蛋白生成及其后续寡聚体和纤维聚集的疾病的药物配方；包括所述取代的吡咯烷化合物的药物配方和/或包括给予该取代的吡咯烷化合物的治疗方法。所述取代的吡咯烷化合物特别是公式I的，其中取代基如规范中所定义。
• Organic Compounds
  申请人：Fairhurst Robin Alec

  公开号：US20090240045A1

  公开（公告）日：2009-09-24

  A compound of formula (I) or stereoisomers or pharmaceutically acceptable salts thereof, and their preparation and use as pharmaceuticals wherein R 1 , R 2 , R 3 , R 4 and W are as defined herein.

  式(I)的化合物，或其立体异构体或药学上可接受的盐，以及它们的制备和用作药物，其中R1、R2、R3、R4和W的定义如本文所述。
• PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN
  申请人：Breitenstein Werner

  公开号：US20100087427A1

  公开（公告）日：2010-04-08

  Novel 3-mono-, 3,4-di- and 3,4,4,-tri-substituted pyrrolidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on inappropriate activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on inappropriate activity of renin; the use of a compound of that class in the treatment of a disease that depends on inappropriate activity of renin; pharmaceutical formulations comprising a said substituted pyrrolidine compound, and/or a method of treatment comprising administering a said substituted pyrrolidine compound, a method for the manufacture of said substituted pyrrolidine compounds, and novel intermediates and partial steps for their synthesis are described. The substituted pyrrolidine compounds are especially of the formula I wherein the substituents are as described in the specification.

  小说3-单一、3,4-二和3,4,4-三取代吡咯烷化合物，这些化合物用于诊断和治疗温血动物，特别是用于治疗依赖于肾素不适当活性的疾病（=失调）；该类化合物用于制备用于治疗依赖于肾素不适当活性的疾病的制药配方；该类化合物用于治疗依赖于肾素不适当活性的疾病；包括所述取代吡咯烷化合物的制药配方和/或包括给予所述取代吡咯烷化合物的治疗方法，以及描述了制备所述取代吡咯烷化合物的新型中间体和部分步骤。所述取代吡咯烷化合物特别是公式I的取代基如说明书所述。
• WO2006/66896
  申请人：——

  公开号：——

  公开（公告）日：——
• WO2007/140980
  申请人：——

  公开号：——

  公开（公告）日：——